接种前免疫标志物可预测脆弱人群对BNT162b2 mRNA疫苗的应答——CONVERS项目,来自一家儿科三级医院的报告
CONVERS研究纳入169名脆弱人群(实体器官移植受者35例、炎症性肠病31例、唐氏综合征42例、HIV感染者36例、原发性免疫缺陷25例)及37名健康对照,评估接种前B/T细胞表型与转录特征同BNT162b2疫苗应答及长期维持的关联。实体器官移植受者T28时抗S抗体滴度<0.8者占31%,其余119人中仅1人T28抗体阴性。接种前未保护者抗原特异性CD40L+ T细胞增幅与类别转换记忆B细胞较低,基线基因表达存在差异。
要点
- 实体器官移植受者T28时抗S抗体滴度<0.8者占31%,其余119人中仅1人抗体阴性。
- 未保护者接种前抗原特异性CD40L+ T细胞增幅与类别转换记忆B细胞低于保护者。
- 接种前B/T细胞表型与基因表达特征与短期和长期记忆维持相关。
核心结论
- 接种前B/T细胞表型与基因表达水平特征与脆弱人群接种BNT162b2后较低免疫原性下的短期和长期记忆维持相关。
- 作者认为这些特征需在更大队列中验证,并可能提供预测评分以支持个体化、更有效的疫苗干预。
研究设计与样本
- CONVERS研究队列纳入脆弱人群169例,包括实体器官移植受者35例、炎症性肠病31例、唐氏综合征42例、HIV感染者36例、原发性免疫缺陷25例,以及健康对照37例。
- 纳入对象为未感染SARS-CoV-2且未接种疫苗者,以SARS-CoV-2特异性抗体和SARS-CoV-2特异性CD4+ T细胞评估疫苗应答。
- 依据T28体液应答分为保护组(抗刺突抗体滴度≥0.8)与未保护组(抗刺突抗体滴度<0.8)。
- 外周血单个核细胞经SARS-CoV-2 Prot-S肽刺激后分选纯化为四个细胞亚群,采用多重RT-PCR(Fluidigm,Biomark)分析。
主要发现
- 实体器官移植受者T28时抗S抗体滴度<0.8者占31%,其余119人中仅1人T28抗体阴性。
- T0时未保护者较保护者抗原特异性CD40L+ T细胞增幅较低、类别转换记忆B细胞较低。
- 基因表达分析显示保护者与未保护者基线存在不同特征,在未刺激与刺激两种实验条件下分别识别出63个和49个差异表达基因。
局限性
- 作者指出这些特征需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whereas several studies have demonstrated the long-term immunogenicity of BNT162b2 vaccine in healthy adults, little evidence was provided in vulnerable populations (VPs) with generally low ability to respond to immunizations. We aimed to identify pre-vaccination immune phenotype and transcriptional signatures in B and T-cell subsets associated with immune response and long-term maintenance upon SARS-CoV-2 vaccination in VPs. METHODS: A cohort of VPs (N = 169) including solid organ transplant recipients (SOT; N = 35), Inflammatory Bowel Disease (N = 31), Down Syndrome (N = 42), people living with HIV (N = 36), primary immune deficiencies (N = 25) and healthy controls (N = 37) were enrolled in the CONVERS Study. SARS-CoV-2 Vaccine responsiveness was evaluated by SARS-CoV-2-specific Ab and SARS-CoV-2-specific CD4+ T cells in VPs naive to infection or vaccination. Based on the humoral response at T28, individuals were classified as Protected (P: anti-spike antibody [anti-S] titer ≥0.8) and Not-Protected (NP: anti-S titer <0.8). Peripheral blood mononuclear cells, after SARS-CoV-2 Prot-S peptides stimulation were sort-purified in four cell subsets and analyzed by multiplexed RT-PCR (Fluidigm, Biomark). RESULTS: SOT presented a significantly lower serological immunogenicity with 31 % of individuals being NP at T28 whereas only 1 out of the remaining 119 resulted Ab negative at T28. At T0, NP individuals showed a lower increase of Ag specific CD40L+ T cells and lower switched memory B cells compared to P patients. Gene-expression analysis revealed distinct signatures at baseline between P and NP individuals with 63 and 49 DEGs identified in two experimental conditions, respectively unstimulated and stimulated. CONCLUSIONS: Pre-vaccination B and T-cell characteristics at both phenotypic and gene- expression level correlate with short- and long- term memory maintenance in VPs with lower immunogenicity upon BNT162b2 vaccine. Such signatures need to be validated in larger cohorts and may provide a predictive score to inform personalized and more effective vaccine interventions.
引用
- Cotugno N, Sanna M, Amodio D, et al. Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital. Vaccine. 2025. PMID: 39947073. doi:10.1016/j.vaccine.2025.126778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。